Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)
GPCR · MARKET VIEW
Market view · as of Aug 10, 2026
Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-0.49
vs $-0.39 est · miss
52-wk position
47.6%
-43.3% vs 52w high · -0.4% 1mo
Price (last ~year)
Structure Therapeutics is a clinical-stage biopharmaceutical company that recently initiated Phase 3 trials for its oral GLP agonist, aleniglipron, for chronic weight management. The company remains pre-revenue, reporting a net loss of $106.2 million for the second quarter of 2026, with $272.6 million in cash and $6.2 million in total debt as of June 30. Shares are trading at $53.14, reflecting a 40.4% gain over the last three months, while analysts maintain a consensus "Moderate Buy" rating with an average price target of $110.55.
Valuation
- Market cap
- $3.78B
- P/B
- 2.789
- EV/EBITDA
- -13.46
- Beta
- -1.507
- Analyst target
- $104.63
Quality & returns
- Operating margin
- 0.0%
- Profit margin
- 0.0%
- ROE
- -15.0%
- ROA
- -11.6%
Price movement
- Last
- $53.14
- 1-month
- -0.4%
- 3-month
- +40.4%
- RSI (14)
- 69
- vs SMA200
- +1.2%
- 52-wk position
- 47.6% -43.3% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $0 | $-118.6M | $-106.2M | $-105.9M |
| 2026-03-31 | $0 | $-89.6M | $-76.2M | $-74.8M |
| 2025-12-31 | $0 | $24.0M | $33.0M | $33.6M |
| 2025-09-30 | $0 | $-73.8M | $-65.7M | $-65.3M |
Recent news
- Neutral Structure Therapeutics Chief Commercial Officer John Joseph Berrios files initial beneficial ownership statement · 2026-08-07
- Neutral Structure Therapeutics Inc. (GPCR) files initial Form 3 for CCO · 2026-08-07
- Neutral Citizens lowers Structure Therapeutics stock price target on GLP agonist · 2026-08-07
- Somewhat-Bullish Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Rating of "Moderate Buy" by Brokerages · 2026-08-07
- Bullish Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights · 2026-08-07
- Bearish BRIEF-Structure Therapeutics Inc. Q2 Net Income USD -106.159 Million · 2026-08-07
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)